Abstracts tagged "osteoblasts and spondylarthropathy"

Abstract Number: 1914 • 2014 ACR/ARHP Annual Meeting
IL-17A Deficiency Promotes Periosteal Bone Formation in a Model of Inflammatory Arthritis
Anita T. Shaw¹, Yukiko Maeda¹, Catherine Manning¹ and Ellen M. Gravallese^1,2, ¹Department of Medicine, Division of Rheumatology, University of Massachusetts Medical School, Worcester, MA, ²Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, Worcester, MA
Background/Purpose: Enthesial and periosteal bone formation in spondyloarthropathies (SpAs) are important sequelae of disease that contribute to patient morbidity. Anti-TNF therapies do not significantly alter…
Abstract Number: 2694 • 2013 ACR/ARHP Annual Meeting
HLA-B27 Expression Prevents Tnfα-Induced Inhibition Of Bone Formation in Vitro In IFNγ/Tnfα-Treated Osteoblasts
Eva Yang¹, Grace Kwon¹, Robert A. Colbert² and Gerlinde Layh-Schmitt¹, ¹NIAMS NIH, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD
Background/Purpose: HLA-B27 predisposes to ankylosing spondylitis (AS), an immune-mediated inflammatory disease associated with osteitis, bone loss, and dysregulated bone formation, most notably in the axial…
Abstract Number: 535 • 2013 ACR/ARHP Annual Meeting
Death Receptor 3 Increases Region-Specific, Osteoblast-Dependent Aberrant New Bone Formation In The Axial Skeleton Of Mice In a Spontaneous Model Of Ankylosing Enthesopathy
Fraser L. Collins¹, Jessica O Williams², Anja C. Bloom¹, Michael D. Stone³, Ernest Choy¹, Edward C. Wang⁴ and Anwen S. Williams⁵, ¹Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, ²Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ³University Hospital Llandough, Cardiff & Vale University Health Board, Cardiff, United Kingdom, ⁴Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, ⁵Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Clinical management of localised bone formation and joint ankylosis constitute major challenges in patients with seronegative inflammatory spondyloarthropathies (SpAs). Whether TNF receptor superfamily members,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].